[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report]

Gan To Kagaku Ryoho. 2022 Nov;49(11):1271-1273.
[Article in Japanese]


A 49-year-old woman presented with abdominal pain. A computed tomography scan revealed a left breast mass with suspected peritoneal dissemination. She had no notable family history of the disease. Following a detailed examination, she was diagnosed with ovarian cancer(Stage ⅢC)and left breast cancer(Stage Ⅰ). After confirming the diagnosis of ovarian cancer with a laparoscopic biopsy, neoadjuvant chemotherapy was scheduled. Due to its efficiency in reducing tumor burden, debulking surgery was also performed. While receiving adjuvant chemotherapy for ovarian cancer, concomitant anastrozole was administered for breast cancer. A pathogenic variant of BRCA2 was subsequently identified. Once adjuvant chemotherapy for ovarian cancer had been completed, a left mastectomy and sentinel lymph node biopsy were performed as management for breast cancer. The patient will continue treatment with anastrozole for breast cancer and olaparib for ovarian cancer and will be followed up appropriately.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Anastrozole / therapeutic use
  • BRCA2 Protein / genetics
  • Breast / pathology
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / surgery
  • Carcinoma, Ovarian Epithelial / surgery
  • Female
  • Humans
  • Mastectomy
  • Middle Aged
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / genetics
  • Ovarian Neoplasms* / surgery


  • Anastrozole
  • BRCA2 protein, human
  • BRCA2 Protein